CJC 1295 No DAC 5 mg/Ipamorelin 5 mg

Dragon Pharma CJC-1295/Ipamorelin

For athletes and physique-focused users looking to support the growth hormone (GH) axis without introducing exogenous GH, combining a GHRH analog with a GHRP is a well-established research approach. Dragon Pharma CJC-1295 No DAC / Ipamorelin delivers a precisely balanced 10 mg peptide blend designed to stimulate natural, pulse-based GH release. When you Buy CJC 1295/Ipamorelin by Dragon Pharma, you are choosing a carefully formulated research product backed by Legit Dragon Pharma quality standards.

CJC-1295 / Ipamorelin Composition

Each 2 mL vial contains a total of 10 mg of lyophilized peptides, consisting of 5 mg CJC-1295 No DAC (Mod GRF-1(29)) and 5 mg Ipamorelin. CJC-1295 No DAC is a short-acting GHRH analog designed to promote pulsatile GH release, while Ipamorelin is a selective GHRP that enhances this signal by reducing somatostatin interference. Together, they are commonly studied for their complementary action on pituitary GH secretion.

Bodybuilding & Performance Support

This peptide combination is widely researched for its role in supporting recovery, sleep quality, and gradual body composition improvements. Growth hormone plays a central role in lipolysis, protein synthesis, and connective tissue repair. By supporting natural GH pulses—particularly during sleep—users often report improved recovery between workouts, better sleep depth, reduced joint discomfort, and a leaner overall appearance over time. Because the body's own GH production is stimulated, results tend to develop steadily rather than abruptly.

Therapeutic Research Background

In research and clinical settings, combinations of GHRH and GHRP compounds are studied for conditions associated with reduced GH output, including age-related GH decline and muscle wasting. Studies show that CJC-1295 and Ipamorelin together can significantly increase GH and downstream IGF-1 levels in a dose-dependent manner, making this blend useful for investigating metabolic health, tissue repair, and long-term recovery processes.

Dosage (Men)

Common research protocols for men involve subcutaneous administration of 100–200 mcg of the blended peptides once or twice daily. Due to the short half-life of both compounds, dosing is typically timed to coincide with natural GH pulses—most commonly upon waking and before sleep. Administration on an empty stomach is recommended to avoid blunting GH release through insulin and glucose spikes.

Dosage (Women)

Female research models generally respond well to lower doses, often in the range of 50–100 mcg per injection, once or twice daily. As with male protocols, empty-stomach administration and conservative dose escalation are important for consistency and tolerance assessment.

Active Life

CJC-1295 No DAC has a plasma half-life of approximately 30 minutes, while Ipamorelin remains active for up to 2 hours. Although the peptides clear quickly, the resulting GH pulse typically lasts several hours, which is why multiple daily administrations are used to mimic physiological GH rhythms.

CJC-1295 / Ipamorelin Side Effects

This blend is known for a relatively mild side-effect profile compared to other GH-related compounds. Ipamorelin is highly selective and does not significantly elevate cortisol or prolactin. Some users may experience transient flushing, mild dizziness, increased hunger, or localized injection-site irritation, particularly during early use.

Contraindications & Precautions

This product should not be used by individuals with known hypersensitivity to peptide compounds. Due to GH and IGF-1 involvement in cellular growth, it is contraindicated in research models involving active malignancies. It should not be used during pregnancy or nursing. Supplied strictly for laboratory research use and not for human consumption.

Overdosage

Excessive dosing may increase the likelihood of temporary side effects such as lethargy, dizziness, or fluid retention. No specific antidote exists; discontinuation and observation are recommended until symptoms resolve.

CJC-1295 / Ipamorelin Stack & Cycle Research

For extended GH support studies, this blend is often combined with MK-677 to provide sustained GH stimulation throughout the day. Researchers focusing on localized IGF-1 activity may add IGF-1 LR3 later in a cycle. For comparative pulse studies, alternating with GHRP-2 is also common. Typical research cycles last 8–12 weeks, followed by an equivalent off period.

Package Presentation

The product is supplied in a sealed, sterile 2 mL clear glass vial containing a white to off-white lyophilized powder. Each vial is clearly labeled with product name, strength, batch number, and expiration date for traceability and quality assurance.

Storage

Store unopened vials in a cool, dry environment away from direct light. Refrigeration is recommended for long-term storage. After reconstitution, keep refrigerated and use within 28 days.

CJC-1295 / Ipamorelin Referrers

The mechanisms behind GHRH and GHRP synergy have been well documented in peer-reviewed literature. Research highlights Ipamorelin's selectivity for GH release and explains how GHRH analogs enhance physiological GH pulsatility. Read more on GHRP synergy and review GHRH analog research.

Third-Party Lab Test

2025-11-07

View Result

5.93 mg/4.96 mg

This product has been independently tested by a third-party laboratory to verify purity and content. The results confirm accurate dosing of the blend, ensuring you receive Legit Dragon Pharma quality for your research.